To directly address the question of whether reprogramming FAO plays a role in ErbB2/HER2-driven breast cancer progression, we established a unique GEMM combining conditional Cpt1a gene targeting (Cpt1aL/L) with mammary epithelial co-expression of oncogenic ErbB2 and Cre recombinase (referred to as NIC) (Fig. 1a)33. This evidence concerns the gene CPT1A and breast carcinoma.